Alzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever" Panel at the Maxim Group's Virtual Healthcare Conference

Author's Avatar
Jun 13, 2023

Alzamend+Neuro%2C+Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that CEO Stephan Jackman will participate as a panelist at the upcoming Maxim Group Virtual Healthcare Conference, to be held between June 20 –22, 2023.